Advertisement
Canada markets closed
  • S&P/TSX

    22,244.02
    +20.35 (+0.09%)
     
  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     
  • DOW

    39,308.00
    -23.90 (-0.06%)
     
  • CAD/USD

    0.7348
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    83.75
    -0.13 (-0.15%)
     
  • Bitcoin CAD

    77,423.12
    -2,412.53 (-3.02%)
     
  • CMC Crypto 200

    1,187.68
    -73.50 (-5.82%)
     
  • GOLD FUTURES

    2,369.40
    0.00 (0.00%)
     
  • RUSSELL 2000

    2,036.62
    +2.75 (+0.14%)
     
  • 10-Yr Bond

    4.3550
    0.0000 (0.00%)
     
  • NASDAQ futures

    20,411.50
    0.00 (0.00%)
     
  • VOLATILITY

    12.26
    +0.17 (+1.41%)
     
  • FTSE

    8,241.26
    +70.14 (+0.86%)
     
  • NIKKEI 225

    40,945.41
    +31.76 (+0.08%)
     
  • CAD/EUR

    0.6790
    -0.0002 (-0.03%)
     

Altimmune to Participate at Leerink Partners Therapeutics Forum

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

ADVERTISEMENT

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com